U.S. Markets open in 4 hrs 48 mins

Viatris Inc. (VIA.MU)

Munich - Munich Delayed Price. Currency in EUR
10.600.00 (0.00%)
As of 09:36AM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.60
Bid10.42 x N/A
Ask10.56 x N/A
Day's Range10.60 - 10.60
52 Week Range8.79 - 13.48
Avg. Volume23
Market Cap13.034B
Beta (5Y Monthly)N/A
PE Ratio (TTM)20.54
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journals

    Viatris completes $3B divestiture of biosimilars business

    Viatris Inc.'s divestiture of its biosimilars business to Biocon was completed Tuesday with a $2 billion cash payment to the Canonsburg pharmaceutical company, the first of an expected $9 billion in divestitures. The terms of the agreement with Biocon Biologics Ltd. also include $1 billion in convertible preferred equity in Biocon Biologics that the companies said amounted to a 12.9% stake in the company plus $335 million in cash in 2024. Viatris (Nasdaq: VTRS) will also provide commercialization and regulatory-related services to Biocon for two years.

  • PR Newswire

    Viatris Completes Biosimilars Transaction with Biocon Biologics

    Viatris Inc. (NASDAQ: VTRS) today announced that it has closed its transaction with Biocon Biologics Limited ("Biocon Biologics"), creating what Viatris expects to be a unique fully vertically integrated global biosimilars leader. Viatris and Biocon Biologics have entered a Transition Services Agreement (TSA) pursuant to which Viatris will provide commercialization and certain other transition services for an expected two-year period intended to ensure business continuity for patients, customers

  • Motley Fool

    Better Dividend Stock: AbbVie or Viatris?

    AbbVie (NYSE: ABBV) and Viatris (NASDAQ: VTRS) have a lot more in common than first glances would suggest. The two were both spun off from larger companies and now deliver above-average dividend yields. In AbbVie's case, it is the patent cliff next year for its immunology drug Humira, the top-selling drug last year other than COVID-19 vaccines.